120 related articles for article (PubMed ID: 34600803)
1. Out-of-pocket costs for commercially insured patients with localized prostate cancer.
Wallis CJD; Joyce DD; Klaassen Z; Luckenbaugh AN; Laviana AA; Penson D; Dusetzina SB; Barocas DA
Urol Oncol; 2021 Dec; 39(12):797-805. PubMed ID: 34600803
[TBL] [Abstract][Full Text] [Related]
2. Cost of care for the initial management of cervical cancer in women with commercial insurance.
Blanco M; Chen L; Melamed A; Tergas AI; Khoury-Collado F; Hou JY; St Clair CM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2021 Mar; 224(3):286.e1-286.e11. PubMed ID: 32818476
[TBL] [Abstract][Full Text] [Related]
3. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
4. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
Joyce DD; Sharma V; Jiang DH; Van Houten HK; Sangaralingham LR; Borah BJ; Kwon ED; Penson DF; Dusetzina SB; Tilburt JC; Boorjian SA
J Urol; 2022 Nov; 208(5):987-996. PubMed ID: 36094864
[TBL] [Abstract][Full Text] [Related]
5. Cost of Care for the Initial Management of Ovarian Cancer.
Bercow AS; Chen L; Chatterjee S; Tergas AI; Hou JY; Burke WM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Obstet Gynecol; 2017 Dec; 130(6):1269-1275. PubMed ID: 29112648
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 1-Year Health Care Costs and Use Associated With Open vs Robotic-Assisted Radical Prostatectomy.
Okhawere KE; Shih IF; Lee SH; Li Y; Wong JA; Badani KK
JAMA Netw Open; 2021 Mar; 4(3):e212265. PubMed ID: 33749767
[TBL] [Abstract][Full Text] [Related]
7. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy.
Martini A; Marqueen KE; Falagario UG; Waingankar N; Wajswol E; Khan F; Fossati N; Briganti A; Montorsi F; Tewari AK; Stock R; Rastinehad AR
JAMA Netw Open; 2020 Mar; 3(3):e201913. PubMed ID: 32232450
[TBL] [Abstract][Full Text] [Related]
8. Effect of health insurance on direct hospitalisation costs for in-patients with ischaemic stroke in China.
Yong M; Xianjun X; Jinghu L; Yunyun F
Aust Health Rev; 2018 Feb; 42(1):39-44. PubMed ID: 28263706
[TBL] [Abstract][Full Text] [Related]
9. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
10. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Out-of-Pocket Costs for Robotic Cancer Surgery in US Adults.
Nabi J; Friedlander DF; Chen X; Cole AP; Hu JC; Kibel AS; Dasgupta P; Trinh QD
JAMA Netw Open; 2020 Jan; 3(1):e1919185. PubMed ID: 31940036
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population.
Grabner M; Bodhani A; Khandelwal N; Palli S; Bonine N; Khera M
J Sex Med; 2017 Jan; 14(1):88-97. PubMed ID: 27939338
[TBL] [Abstract][Full Text] [Related]
14. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Liang MI; Chen L; Hershman DL; Hillyer GC; Huh WK; Guyton A; Wright JD
Gynecol Oncol; 2021 Mar; 160(3):793-799. PubMed ID: 33375989
[TBL] [Abstract][Full Text] [Related]
15. Financial toxicity associated with treatment of localized prostate cancer.
Imber BS; Varghese M; Ehdaie B; Gorovets D
Nat Rev Urol; 2020 Jan; 17(1):28-40. PubMed ID: 31792431
[TBL] [Abstract][Full Text] [Related]
16. Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
Rodriguez-Acevedo AJ; Chan RJ; Olsen CM; Pandeya N; Whiteman DC; Gordon LG
BMC Cancer; 2021 Sep; 21(1):1055. PubMed ID: 34563142
[TBL] [Abstract][Full Text] [Related]
17. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
Nguyen PL; Gu X; Lipsitz SR; Choueiri TK; Choi WW; Lei Y; Hoffman KE; Hu JC
J Clin Oncol; 2011 Apr; 29(12):1517-24. PubMed ID: 21402604
[TBL] [Abstract][Full Text] [Related]
18. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
Shih YT; Xu Y; Bradley C; Giordano SH; Yao J; Yabroff KR
J Natl Cancer Inst; 2022 Oct; 114(10):1392-1399. PubMed ID: 36099068
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
[TBL] [Abstract][Full Text] [Related]
20. Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada.
de Oliveira C; Bremner KE; Ni A; Alibhai SM; Laporte A; Krahn MD
J Cancer Surviv; 2014 Mar; 8(1):9-20. PubMed ID: 23975612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
